Clinical practice guidelines for Obsessive-Compulsive Disorder

Y.C. Janardhan Reddy, A. Shyam Sundar, Janardhanan C. Narayanaswamy, Suresh Bada Math
Department of Psychiatry, OCD Clinic, National Institute of Mental Health & Neurosciences (NIMHANS), Bangalore, Karnataka, India

INTRODUCTION

Obsessive-compulsive disorder (OCD) is a common psychiatric illness with lifetime prevalence of 1-3% [1]. It is the fourth-most common psychiatric illness and a leading cause of disability. OCD is associated with significant impairment in functioning, quality of life and disability. If untreated, OCD is a chronic illness with a waxing and waning of symptoms. A recent meta-analysis of long-term naturalistic prospective studies demonstrated that nearly a half of patients experience remission with much higher rates of remission in Indian patients compared to those in the west [2]. Early diagnosis and appropriate treatment may improve outcomes. Despite OCD being a common mental illness, most seek treatment after several years of suffering. Those who suffer from OCD tend to be secretive about their symptoms and suffer from shame and embarrassment. Less than a third of OCD sufferers receive appropriate pharmacotherapy and even less receive evidence-based psychotherapy.

Symptoms
The hallmarks of OCD are presence of obsessions and compulsions. Obsessions are repetitive, unwanted, intrusive thoughts, images or urges that are mostly ego-dystonic and cause severe distress or anxiety. Compulsions (or rituals) are repetitive behaviours or mental acts that are performed in response to an obsession to reduce anxiety/distress or prevent a dreaded consequence. Obsessions and compulsions are time consuming, distressing and are often resisted unsuccessfully. Clinical manifestations of OCD are remarkably similar across cultures and geographic locations. Common obsessions and compulsions and symptom dimensions identified through factor-analytical studies are shown in Table 1.

Diagnosis
Many people experience intrusive thoughts and exhibit repetitive behaviours. A diagnosis of OCD is made only if symptoms are time consuming (e.g., more than an hour per day), distressing or cause significant interference in functioning. This is reflected in DSM-5 diagnosis of OCD and in the upcoming ICD-11 [3]. The ICD-11 criteria for OCD are likely to be very similar to the DSM-5 criteria [3, 4]. The ICD-11 may include an insight specifier along the same lines as DSM-5. There are sweeping changes to the description of OCD in the proposed ICD-11. Duration criteria and subtyping of OCD may be removed in the revision for lack of evidence and clinical relevance. In ICD-10, a diagnosis of OCD was discouraged in the presence of schizophrenia, tic disorder or depression. This criterion too may be removed paving the way to make a diagnosis of OCD even in the presence of these comorbid disorders.

Another major change to the diagnosis of OCD is creation of OCD and related disorders in DSM-5 (and in the ICD-11) and exit from the group of anxiety disorders. Many disorders are included in this group: body dysmorphic...
Table 1: Common symptoms of OCD

| Obsessions |
|------------|
| **Contamination related obsessions** |
| • Concern/disgust with bodily secretions and waste such as stools and urine |
| • Fear of dirt or germs/infections, concern with sticky substances |
| • Fear of getting ill because of contaminants (e.g., AIDS) |
| **Sexual obsessions** |
| • Unwanted, forbidden sexual thoughts, images or urges about strangers, family friends, etc |
| • Sexual thoughts of molesting children, thoughts of sexual identity (am I a gay?) |
| **Harm/aggression related obsessions** |
| • Fear might harm self or others (fear of jumping off the building, fear of harming babies, stabbing a friend, running over pedestrians while driving etc) |
| • Violent/horrific images (murders, mutilated bodies, accidents) |
| • Fear of uttering obscenities |
| **Religious/blasphemy** |
| • Sacrilege and blasphemy (blasphemous thoughts, fear of uttering insults to God) |
| • Excessive concern about right/wrong, morality |
| **Pathological doubts about daily activities (doubts of having not locked doors, turned off gas knobs)** |
| • Concern about things being not properly aligned, symmetrical, perfect or exact |
| • With magical thinking (child may have an accident if things are not properly arranged in kitchen) |
| **Miscellaneous** |
| • Need to know/remember (number plates, advertisements etc.) |
| • Intrusive non-violent images, thoughts |
| • Superstitious fears (passing a cat, cemetery) |
| • Lucky/unlucky numbers, colors |

| Compulsions |
|------------|
| **Washing/Cleaning** (excessive or ritualized hand washing, showering, bathing, brushing/excessive cleaning of household items, floors, kitchen vessels etc) in response to contamination obsessions |
| **Checking** |
| • In response to pathological doubts (appliances, locks, stove, doors) |
| • To prevent harm to self or others (check to make sure that you have not caused accident, examining for injuries etc.) |
| **Repeating** |
| • Re-reading or rewriting because you didn’t understand or write properly |
| • Repeating routine activities (going in and out of doorway, sit and stand up repeatedly, repeating till you feel just right) |
| **Counting (money, floor tiles)** |
| **Ordering and arranging (often till you feel just right)** |
| **Miscellaneous** |
| • Mental rituals (praying, replacing bad thought with good thought) |
| • Superstitious behaviours |
| • Need to tell/ask/confess |

**Symptom dimensions [41]**

- Contamination fears and cleaning/washing
- Forbidden thoughts (aggression, sexual, religious, and somatic obsessions and checking compulsions)
- Symmetry (symmetry obsessions and repeating, ordering, and counting compulsions)
- Hoarding (hoarding obsessions and compulsions)

OCD is often comorbid with other psychiatric disorders. Bipolar disorder, in particular type 2, is reported to be not uncommon in OCD [5]. Similarly, OCD is not uncommon in those with primary diagnosis of bipolar disorder [6, 7]. OCD when comorbid with bipolar disorder tends to run an episodic course [8] with worsening of symptoms in depressive phases and improvement in hypomania/mania phases. It is important to recognise OCD-bipolar comorbidity because of treatment implications. The specific serotonin-reuptake inhibitors (SSRIs) traditionally used to treat OCD may induce switch to mania or rapid cycling course.

Obsessive-compulsive symptoms and OCD are not uncommon in schizophrenia. Nearly a third of schizophrenia patients report OC symptoms or OCD. Presence of OCD may have a negative effect on the long-term course of schizophrenia. Therefore treatment of OCD with SSRIs and cognitive-behavior therapy (CBT)/behavior therapy (BT) may have to be considered although there is not much of systematic evidence supporting their efficacy in treatment of OCD in schizophrenia.

**COMMON INGREDIENTS OF MANAGEMENT PLAN**

Common ingredients of managing OCD include the following:

1. Detailed assessment of symptoms and comorbid patterns including suicidal behaviours either by unstructured clinical interview alone or supplementation with structured assessments.
2. Decision on setting for treatment (outpatient vs. inpatient...
Differential diagnoses to consider

Personality disorders
- Obsessive-compulsive personality disorder
- Anxious-avoidant personality disorder
- Borderline personality disorder
- Schizotypal personality

OCD related disorders
- Body dysmorphic disorder
- Trichotillomania
- Skin picking disorder
- Tic disorders

Attention deficit hyperactivity disorder

Oppositional defiant disorder

Personality disorders
- Obsessive-compulsive personality disorder
- Anxious-avoidant personality disorder
- Borderline personality disorder
- Schizotypal personality

Differential diagnoses to consider

- Depression (depressive ruminations are usually ego-syntonic, reflective of depressive cognitions such as self-criticism, failure, regret, guilt, pessimism without any compulsions)
- Generalized anxiety disorder (anxious ruminations are about real-life concerns and not associated with compulsions)
- Body dysmorphic disorder (concerns limited to physical appearance)
- Trichotillomania (limited to hair pulling)
- Skin picking disorder (confined to excessive skin picking)
- Hoarding disorder (difficulty in discarding or parting with possessions, accumulation of possessions; not secondary to obsessions)
- Eating disorders (confined to weight and food)
- Tics (often preceded by premonitory sensations and not aimed at neutralizing obsessions)
- Psychotic disorders (Even poor insight/delusional OCD is associated with typical obsessional content and compulsions whereas delusions have persecutory, grandiose themes with other symptoms such as hallucinations or formal thought disorder)
- Obsessive-compulsive personality disorder (enduring and pervasive pattern of excessive preoccupation with perfectionism, orderliness and rigid control; rigidity, stubbornness, scrupulosity and over conscientiousness. Typically ego-syntonic. No obsessions and compulsions)

Table 2: Comorbid disorders in OCD

| Mood disorders         |                      | Anxiety disorders          |                      | OCD related disorders     |                      | Personality disorders                    |                      |
|------------------------|----------------------|---------------------------|----------------------|----------------------------|----------------------|------------------------------------------|----------------------|
| Major depression       |                      | Panic disorder             |                      | Body dysmorphic disorder   |                      | Obsessive-compulsive personality disorder|
| Dysthymia              |                      | Generalized anxiety disorder|                      | Trichotillomania          |                      | Anxious-avoidant personality disorder    |
| Bipolar disorder       |                      | Social Phobia             |                      | Skin picking disorder      |                      | Borderline personality disorder         |

ASSESSMENT AND EVALUATION

In routine clinical practice, use of structured / semistructured interviews and rating scales may not be necessary. They are optional. However, they may be used when the clinician needs supplementary information. A list of useful instruments in the assessment of OCD is provided in Table 3.

The Yale-Brown Obsessive-Compulsive Scale (YBOCS) is the most widely used severity rating scale for OCD in both adults [9] and children [10] and is considered a gold standard instrument to measure severity of OCD. It is a 10-item observer-rating scale, also available as self-rated instrument. It measures the overall severity of obsessive-compulsive symptoms for the preceding week. The YBOCS is a global measure of symptoms and does not provide severity of individual symptom dimensions. A total score of ≥ 16 is considered to be indicative of clinically significant OCD. The YBOCS severity scale also has an associated symptom check list of 15 categories of obsessions and compulsions including miscellaneous symptoms. The checklist elicits both current (1 month) and past symptoms.

On the YBOCS item-11 insight scale, the insight is graded as follows: 0 = excellent (fully rational thinking), 1= good insight (readily acknowledges absurdity or excessiveness but has some lingering doubts), 2 = fair insight (reluctantly admits absurdity, but waives; has some unrealistic fear but no fixed conviction), 3 = poor insight (overvalued ideas; maintains they are not unreasonable or excessive, but acknowledges validity of contrary evidence), and 4 = lack of insight (delusional). A higher score on the Y-BOCS item-11 indicates poorer insight.

FORMULATING A TREATMENT PLAN

Formulating a treatment begins with correct diagnosis of OCD as per the DSM or ICD classificatory systems. When feasible a structured clinical interview is recommended to obtain a comprehensive account of patient’s problems. Once a diagnosis is established, a detailed assessment of symptom profile is mandatory. Family members often accommodate patient’s rituals and contribute to poor outcome. In most severely ill patients, an elaborate family assessment may be needed. Once assessment is complete, short-term and long-term goals of treatment have to be established. Enhancing treatment adherence is a vital aspect of formulating a treatment plan. It is important to educate patients about lag in the onset of action of drugs and that improvement may occur over several months of continuous treatment. Brief education about basic principles of psychotherapy should be explained if psychotherapy is being planned. Essentials of formulating a treatment plan are summarized in Table 4.

All patients and their immediate family members should be provided psychoeducation about OCD (Table 5).
CHOICE OF TREATMENT SETTINGS

In the Indian scenario, treatment is either on an outpatient or an inpatient basis. Outpatient treatment is usually sufficient for most OCD patients who are mild to moderately ill and for those who are likely to be adherent to treatment. Patients may be followed-up at periodic intervals, initially once in a month or two and subsequently at longer intervals depending upon the response to treatment and tolerability and side-effects. Hospital treatment may be considered for those who are at high suicide risk, dangerous to self or others, and intolerant to side-effects. Many severely ill and treatment-resistant patients may require prolonged (2-3 months) hospitalization for intensive treatment with CBT and for rationalization of pharmacotherapy. Inpatient care may also be required for severe depression, mania or psychosis that may be comorbid with OCD. Admission in rehabilitation services may be necessary for some patients who may not have benefited from standard treatments including inpatient care.

PHARMACOLOGICAL TREATMENT

The clinical practice guideline is framed based on a review of relevant scientific literature. As a first step, we framed relevant questions which arise in the minds of the practitioner while treating a patient suffering from OCD. A literature search was conducted in PubMed to answer these questions. We also reviewed the existing guidelines on treatment of OCD [11-14]. After a thorough literature review, the treatment strategies were rated based on the Strength of Recommendation Taxonomy (SORT) [15].

Consistent evidence from multiple randomized controlled trials (RCT) constitutes the highest level of evidence for a recommendation. However, the external validity of RCTs has been questioned due to the rigid protocols in undertaking the studies. A practitioner may make a clinical decision based on the available evidence considering other relevant factors that influence the decision making process. A non-exhaustive list of these factors might include psychiatric and other medical comorbidities, previous treatment trials, affordability, accessibility, hypersensitivity, side-effect profile, patients’ values etc.

RELEVANT CLINICAL ISSUES

1. First-line pharmacological treatment for OCD

Meta-analyses of RCTs show that selective-serotonin reuptake inhibitors (SSRIs) are significantly more effective than placebo in the treatment of OCD [16]. SSRIs are associated with many adverse effects but are usually well tolerated. The only other medication which has shown to be consistently effective in OCD is the serotonergic tricyclic antidepressant clomipramine. Clomipramine has been found to be significantly more effective than placebo in multiple RCTs and meta-analysis of RCTs [16]. Network meta-analysis comparing the efficacy of clomipramine vs. SSRIs failed to find any efficacy advantage over SSRIs [16]. Most head-to-head comparison trials have not found any significant difference between the efficacy of clomipramine and SSRIs [17]. Further, meta-analyses and individual RCTs have found that the tolerability of clomipramine is worse than that of SSRIs

| Table 3: Commonly used instruments to assess OCD (optional) |
|---|
| **Diagnostics interview schedules** |
| • The Mini International Neuropsychiatric Interview (MINI) [42] |
| • Structured Clinical Interview for DSM-5 (SCID-5) [43] |
| **Severity rating scales** |
| • Yale-Brown Obsessive-Compulsive Scale (YBOCS): symptom checklist and severity rating scale (adult and child versions) [9,10] |
| • Dimensional YBOCS (DYBOCS) [44] |
| **Scales to assess insight in OCD** |
| • Yale-Brown Obsessive-Compulsive Scale (YBOCS), Item 11 [9] |
| • Brown-Assessment of Beliefs Scale (BABS) [45] |
| • Overvalued Ideas scale (OVIS) [46] |
| **Obsessive-beliefs questionnaire (OBQ)** to measure beliefs underlying obsessions [47] |
| The Family Accommodation Scale (FAS) assesses the degree to which family members of those with OCD accommodate patient’s compulsions/rituals [48] |

| Table 4: Essentials of formulating a treatment plan |
|---|
| **Establishing a diagnosis if OCD** |
| Diagnosis of comorbid disorders (optional structured clinical interview) |
| Detailed evaluation for a range of OCD symptoms (clinical interview/ YBOCS or similar check list) |
| **Detailed symptom evaluation** |
| • Identify principal symptoms that are the target of treatment (especially useful to identify principal symptoms if CBT is planned) |
| • Identify proxy compulsions, avoidance and safety behaviours |
| • Determine level of insight |
| • Assess family accommodation of patient’s rituals |
| **Short-term goals** |
| • To achieve clinical response and if possible remission |
| • Remission of depression, if comorbid |
| • Help deal with suicidal thoughts, behaviour if any |
| • To determine tolerability to medicines |
| • Identify and manage side-effects |
| **Long-term goals** |
| • Achieve recovery |
| • Restore psychosocial functioning and enhance quality of life |
| • Long-term treatment to prevent relapses |
| **Enhancing treatment adherence** |
| • Psychoeducation to the patient and family members |
| • Provide education materials to patient and family members |
| • Deal with unrealistic expectations of quick recovery; educate patients and family about lag in the onset of action of drugs and that improvement may occur over several months |
| • Sensitive patient about potential side-effects and help to deal with them |
| • Use medicines that are effective, easily available and affordable |
| • Treat comorbid disorders and personality disorders if any; if left untreated may contribute to poor treatment adherence |
| **Enhancing adherence to psychotherapy (CBT)** |
| • Detailed education about principles behind exposure and response prevention |
| • Reassure that exposure and response prevention will be graded and tasks will be determined based on collaborative approach |
| • Emphasize the role of motivation, home-work compliance and need to tolerate some anxiety |
| • Reduce unrealistic expectations of quick recovery |
Choice of SSRI
Meta-analyses comparing the different SSRIs [16] and direct head-to-head comparisons [17,18] have not shown superiority of any one SSRI over the other. SSRIs differ to some extent in their propensity to cause certain adverse effects and drug interactions. However, there is no unequivocal evidence to suggest that these differences may be clinically meaningful. Recently, concerns have been raised regarding cardiac adverse effects with high dose of citalopram, which is commonly used in OCD. Hence, high-dose citalopram may be used with caution in those with risk for arrhythmias.

THE PRACTITIONER IS RECOMMENDED TO CHOOSE AN SSRI FOR AN INDIVIDUAL PATIENT BASED ON FACTORS SUCH AS PREVIOUS RESPONSE, COMORBIDITY, TOLERABILITY, ACCEPTABILITY, ADVERSE EFFECTS, COST AND DRUG INTERACTIONS.

Dose of SSRI
It is generally recommended that OCD be treated with a higher dose of SSRI than that used in depression (Table 5). A meta-analysis of fixed-dose comparison studies have found a greater efficacy with higher doses of SSRI (60-80 mg fluoxetine equivalent) compared to medium (40-50 mg fluoxetine equivalent) and low doses (20-30 mg fluoxetine equivalent) [19]. However, all three dose ranges were significantly more effective than placebo. The increased efficacy comes at the cost of poor tolerability as evidenced by increased dropouts due to adverse effects [19]. A review of individual fixed-dose comparison studies found that the dose-response relationship is more evident for escitalopram, fluoxetine and paroxetine, while it is less clear-cut for citalopram and sertraline [17]. Clomipramine has not been tested in such fixed dose comparison studies. However, most studies have employed a flexible dosing at 150-250 mg [17]. It should be remembered that there is likely to be inter-individual differences in

### Table 5: Components of psychoeducation

- Obsessions and compulsions are symptoms of OCD and that they are similar in most people who suffer from OCD; OCD is a brain disorder
- Obsessions are not a reflection of one’s character or unresolved mental conflicts
- Explain the link between the components-Obsessions, compulsions and distress
- Clarify myths and misconceptions about the illness
- Explain the biological and psychological basis of OCD: OCD is a problem of aberrant functioning of certain brain circuits involved in disregarding unwanted thoughts, dysfunction of certain neurotransmitter systems such as serotonin and glutamate, faulty interpretation and excessive importance given to certain intrusions resulting in manifestation of obsessions
- Discuss the course and outcome of OCD-regarding the waxing and waning course with optimism that outcome is good in a majority of the people if adequately treated
- Provide information regarding the available treatment strategies: pharmaco therapy and cognitive behavior therapy
- Sensitize with the idea that treatment is a continued process and often long-term
- Educate that medications take time to work, sometimes as long as few months before appreciable improvement is seen
- Psychological treatment too needs sustained efforts and sometimes booster sessions
- Prevention of relapse addressed within the general context of OCD as a chronic disorder
- Educate the family regarding the need to reduce expressed emotions such as criticality, accommodative behaviors and proxy compulsions; thus being supportive in the treatment process

[13, 17]. The anticholinergic, cardiac and neurological side effects of clomipramine may be problematic in this regard.

CONSIDERING THE CONSISTENT EFFICACY AND BETTER TOLERABILITY, GUIDELINES RECOMMEND SSRIs AS FIRST LINE TREATMENT FOR OCD (TABLE 6).

### Table 6: Medications recommended as monotherapy in OCD

| Drug         | Suggested dosage | Strength of recommendation* |
|--------------|------------------|-----------------------------|
| Escitalopram | 20-30 mg         | A                           |
| Fluoxetine   | 60-80 mg         | A                           |
| Fluvoxamine  | 200-300 mg       | A                           |
| Paroxetine   | 40-60 mg         | A                           |
| Sertraline   | 150-200 mg       | A                           |
| Citalopram   | 40-60 mg         | A                           |
| Clomipramine | 150-225 mg       | A                           |
| Venlafaxine  | 225-300 mg       | B                           |

*Based on modified Strength of Recommendation Taxonomy (SORT)[15]

A – Consistent, good-quality patient-oriented evidence i.e., Meta-analysis of Randomized controlled trials (RCT) with consistent findings or high quality individual RCT
B – Inconsistent or limited-quality patient-oriented evidence i.e., systematic review/meta-analysis of lower quality clinical trials or studies with inconsistent findings/lower quality clinical trial/cohort study/case-control study
C – Consensus based clinical guidelines extrapolations from bench research, disease-oriented evidence, usual practice, opinion, case-series

### Table 7: Predictors of response to SSRLs

| Clinical predictors of poor response |
|-------------------------------------|
| Early age of onset                  |
| Longer duration of illness          |
| Poor insight                        |
| Presence of hoarding, sexual/religious obsessions, cleaning/washing, repeating/counting compulsions |
| Comorbidities in the form of tics and depressive disorder |
| Comorbid schizotypal, borderline and anxious avoidant personality disorders |

**Neuroimaging predictors**
- Lower baseline orbitofrontal cortex (OFC) and anterior cingulate cortex (ACC) metabolism and greater pretreatment caudate metabolism predicted better response (PET studies)
- Reduction in thalamic volume and increase in OFC volume is associated with SSRI response (structural MRI)
- Increased dorso-lateral prefrontal cortex (DLPFC) activation with Stroop task and decreased activation of frontal regions with symptom provocation task predicted good response

**Genetic predictors**
- Specific polymorphisms in the promoter region of serotonin transporter (5 HTTLPR) associated with treatment response
- CYP2D6 polymorphisms associated with SSRI response

Ref:[49]
pharmacokinetic profile of drugs due to intrinsic variations in drug metabolism and drug interactions.

**GUIDELINES RECOMMEND TREATMENT OF OCD WITH HIGHER DOSE OF SSRIs. HOWEVER, IF AN INDIVIDUAL PATIENT IS NOT ABLE TO TOLERATE HIGHER DOSE, LOW TO MEDIUM DOSE TREATMENT CAN BE CONSIDERED.**

*Duration of trial and dose titration*
A recent meta-analysis of 17 RCTs found that SSRIs separate from placebo as early as 2 weeks and that majority of improvement occurs early on in the course of treatment [20]. However, improvements seen early in the course of treatment may not be always clinically meaningful. In many patients, clinically meaningful improvements may be seen only after weeks or months of treatment. It is recommended that an adequate trial of a SSRI (or clomipramine) should be at least for 12 weeks to account for the lag in the onset of action. The APA guidelines recommend upward titration to the maximum FDA-approved doses by 4-6 weeks and continuation in that dose for another 6-8 weeks or so to determine efficacy [11]. Certain clinical and biological predictors of treatment
response to SSRIs have been identified but they are not robust predictors (Table 7).

GUIDELINES RECOMMEND CONTINUING MAXIMALLY TOLERATED EFFECTIVE DOSE OF A SSRI FOR AT LEAST 12 WEEKS FOR JUDGING ITS EFFICACY. GUIDELINES ALSO RECOMMEND DOSE ESCALATION TO EFFECTIVE DOSE RANGES WITHIN 4-6 WEEKS AND CONTINUATION IN THE SAME DOSE FOR ANOTHER 6-8 WEEKS.

2. Other medications that can be tried as monotherapy in OCD
Venlafaxine, a serotonin-norepinephrine reuptake inhibitor with preferential serotonergic action, has been studied in comparison to paroxetine in a double blinded study and clomipramine in a single blinded study. The studies found no difference in the efficacy between venlafaxine and the comparator agents in acute control of OCD.

Given the absence of evidence from placebo-controlled trials, venlafaxine is not the first-line treatment for OCD. Hence, the guidelines consider venlafaxine as a second-line monotherapy agent in the treatment of OCD.

Mirtazapine has been studied as a monotherapy in two small open-label trials with inconsistent findings. Therefore, mirtazapine cannot be recommended as monotherapy in treatment of OCD.

3. Treatment strategy for non-responders to first-line treatment
Definitions of treatment outcome [21] are given in Table 8. Estimates suggest that around 40-70% patients show an adequate response to a trial of SSRI with a remission rate of 10-40% [16]. Clinicians often face the subsequent challenge of partial and non-response to SSRIs. Continuing improvement has been noticed with prolonged trial of SSRIs as discussed above. Hence, the initial trial may be continued further if there is evidence of ongoing improvement. A general treatment algorithm for OCD and for non-responders to SSRIs is shown in Figures 1 and 2 respectively.

a. Switching to another medication
Switching to another first-line medication has been found to be effective; experts provide a rough estimate of 40-50% response rate for the second SSRI and decreasing response rates with further trials. Switching to a second SSRI is suggested for non-responders to a first SSRI. In partial responders, changing medication may entail loss of the response to the earlier medication. Hence, switching is recommended in partial responders only if there are severe persisting symptoms or upon failure of other augmenting strategies such as CBT and atypical antipsychotics.

b. Switching / Augmenting with CBT/BT
It is uncertain whether initiating a combination of BT/CBT simultaneously with SSRI is advantageous compared to either treatment alone. However, CBT/BT has been proven to be effective as an augmenter in partial/non-responders to SSRIs [18, 22, 23]. Where feasible, CBT/BT is a potential first-line augmenting option for partial/non-responders to SSRI treatment.

c. Augmenting with another medication (Table 9)
The following medications have been commonly tried as augmenters to SSRIs. Atypical antipsychotics, risperidone and aripiprazole have the best evidence.

i Antipsychotics
Antipsychotics are the most widely studied augmenting agents of SSRIs [23]. The literature on antipsychotic augmentation is fraught with methodological limitations.
including small sample sizes, varying doses and duration of treatment with both antipsychotics and concomitant SSRIs, varying degree of treatment resistance etc. Two recent meta-analyses of 14 RCTs on antipsychotic augmentation found that antipsychotic as a group was significantly more effective than placebo in decreasing YBOCS scores [24, 25]. About a third of patients responded to antipsychotic augmentation. Aripiprazole and risperidone are consistently found to be effective as augmenting agents. The evidence for haloperidol should be interpreted with caution as it was based on a single study. A fairly large RCT comparing CBT, risperidone and pill placebo augmentation of SSRIs found that risperidone did not separate from placebo in augmenting efficacy [26]. This study has raised questions on the efficacy of risperidone as an augmenter. Quetiapine and olanzapine have not been consistently found to be effective, while other antipsychotics have not been studied adequately. Meta-analyses do not throw any light on adequate dose and duration of antipsychotic treatment [24]. Antipsychotics should be used in low doses (e.g., 1-3 mg of risperidone, 5-10 mg aripiprazole) for a period of at least 8 weeks for an adequate trial. Use of antipsychotics in the long-run should be considered after weighing the benefits and risks of long-term use.

**BASED ON THE AVAILABLE EVIDENCE, ARIPIPRAZOLE AND RISPERIDONE MAY BE CONSIDERED THE FIRST CHOICE FOR PHARMACOLOGICAL AUGMENTATION**

**ii. Glutamatergic agents**

There is a strong theoretical rationale supporting the use of glutamatergic drugs in OCD. The following glutamatergic agents have been studied in OCD [23]:

**References:**

1. Reddy, et al.: CPGs for OCD

**Table 8: Definitions of treatment outcome in OCD**

| Conceptual Definition | Operationalization |
|-----------------------|-------------------|
| **TREATMENT RESPONSE** | **PARTIAL RESPONSE** |
| A clinically meaningful reduction in symptoms (time, distress, and interference associated with obsessions, compulsions, and avoidance) relative to baseline severity in an individual who meets diagnostic criteria for OCD |
| A ≥35% reduction in (C) Y-BOCS scores plus CGI-I rating of 1 (‘very much improved’) or 2 (‘much improved’), lasting for at least one week |
| **REMISSION** |
| The patient no longer meets syndromal criteria for the disorder and has no more than minimal symptoms. Residual obsessions, compulsions, and avoidance may be present but are not time consuming and do not interfere with the person’s everyday life |
| If a structured diagnostic interview is feasible, the person no longer meets diagnostic criteria for OCD for at least one week |
| **RECOVERY** |
| The patient no longer meets syndromal criteria for the disorder and has had no more than minimal symptoms. Residual obsessions, compulsions, and avoidance may be present and slightly fluctuate in severity over time but, overall, they are not time consuming and do not interfere with the person’s everyday life and therefore require no further treatment. The clinician may begin to consider discontinuation of treatment or, if the treatment continues, the aim is to prevent relapse |
| If a structured diagnostic interview is feasible, the person no longer meets diagnostic criteria for OCD for at least one year |
| **RELAPSE** |
| After response or remission or recovery was achieved, the patient experiences a return of symptoms. For patients who were in remission or recovered, obsessions, compulsions, and avoidance are again sufficiently time consuming, distressing, and impeding for the individual to meet diagnostic criteria for OCD |
| For responders who did not necessarily remit/recover: The person no longer meets the definition of ≥35% reduction on (C) Y-BOCS scores (relative to pre-treatment) plus CGI-I rating of 6 (‘much worse’) or higher for at least one month |

**Abbreviations:** CGI-I – Clinical Global Impression Improvement; CGI-S – Clinical Global Impression Severity; (C) Y-BOCS – (Children’s) Yale-Brown Obsessive Compulsive Scale; OCD – Obsessive-Compulsive Disorder. Ref: [21]. This table is reprinted with permission from the lead author of the Delphi survey. The table is not part of the publication.
Table 9: Pharmacological augmenting agents in OCD

| Drug            | Suggested dosage | Strength of recommendation |
|-----------------|------------------|----------------------------|
| Aripiprazole    | 5-10 mg          | A                          |
| Risperidone     | 1-3 mg           | A                          |
| Haloperidol     | 2.5-10 mg        | B                          |
| Memantine       | 10-20 mg         | B                          |
| Lamotrigine     | 100 mg           | B                          |
| Ondansetron     | 2-4 mg twice a day | B                          |
| Granisetron     | 1 mg twice a day | B                          |

$ - Rough estimate based on available evidence
*Based on modified Strength of Recommendation Taxonomy (SORT)[15]
A – Consistent, good-quality patient-oriented evidence i.e., Meta-analysis of Randomized controlled trials (RCT) with consistent findings or high quality Individual RCT
B – Inconsistent or limited-quality patient-oriented evidence i.e., systematic review/meta-analysis of lower quality clinical trials or studies with inconsistent findings/lower quality clinical trial/cohort study/case-control study
C – Consensus based clinical guidelines extrapolations from bench research, disease-oriented evidence, usual practice, opinion, case-series

iv. Other augmenting agents
Buspirone, lithium and clonazepam have not been found effective and hence are not recommended as augmenting agents. The safety and efficacy of psychostimulants and opioid drugs have to be systematically studied before they are recommended for routine clinical use. Intravenous ketamine has been found to have acute anti-obsessive effects in a “proof-of-concept” study, which needs replication and long term evaluation before the strategy can be recommended for routine clinical use.

d. Other experimental strategies
While there appears to be some short-term benefits for intravenous clomipramine in treatment resistant patients, the long term benefits are uncertain. This formulation is not available in India and is not recommended at present for clinical use. There are a few uncontrolled trials demonstrating the utility of higher than recommended doses of SSRIs (up to 400 mg of sertraline, 40-50 mg of escitalopram) in resistant patients. This strategy should be considered experimental and may be used only in resistant patients after exhausting other regular safer options.

ROLE OF OTHER NON-SOMATIC TREATMENTS

Around 20% of patients do not respond to available pharmacological and psychological treatments. Neuromodulatory and neurosurgical treatments targeting the cortico-striato-thalamo-cortical (CSTC) circuits have been tried in resistant patients.

NON-INVASIVE BRAIN STIMULATION TECHNIQUES

1. Electroconvulsive therapy(ECT)
ECT has not been systematically evaluated for the treatment of OCD. Available evidence, in the form of case reports and case series, do not provide evidence for the efficacy of ECT [28]. Hence, ECT is not recommended as a treatment for OCD and may be considered for the treatment of comorbid conditions like severe mood and psychotic disorders, if indicated.

2. Repetitive transcranial magnetic stimulation (rTMS)
rTMS entails the possibility of non-invasive and focal stimulation of superficial cortical regions, thereby increasing or decreasing their excitability based on the frequency of stimulation. The regions implicated in OCD are usually not accessible with available technology of rTMS. Hence rTMS has been tried in superficial cortical regions which have connections with other deeper structures implicated in OCD. Controlled trials of low frequency or high frequency rTMS over either dorsolateral prefrontal cortex (DLPFC) have yielded conflicting results.

iii. Serotonergic agents
5HT-3 antagonists including ondansetron and granisetron are reported to be effective and well tolerated in small RCTs [27]. However, due to the methodological limitations of the individual studies, 5HT-3 antagonists are recommended as second line augmenting agents along with glutamatergic agents.

Preliminary evidence suggests that clomipramine can be an effective augmenting agent. Clomipramine and SSRI combination should be used cautiously, especially with fluoxetine and fluvoxamine, as they may increase clomipramine related adverse effects (including serious events like seizures, cardiac effects, serotonin syndrome) due to pharmacokinetic interactions. Clomipramine augmentation of SSRI may be tried but adequate precautions need to be taken keeping in mind the potential adverse effects of the combination.

Mirtazapine augmentation has been found to hasten the response with no significant long term benefits [23] and hence may be considered as an augmenting agent in partial responders and non-responders.

Based on modified Strength of Recommendation Taxonomy (SORT)[15]
A – Consistent, good-quality patient-oriented evidence i.e., Meta-analysis of Randomized controlled trials (RCT) with consistent findings or high quality Individual RCT
B – Inconsistent or limited-quality patient-oriented evidence i.e., systematic review/meta-analysis of lower quality clinical trials or studies with inconsistent findings/lower quality clinical trial/cohort study/case-control study
C – Consensus based clinical guidelines extrapolations from bench research, disease-oriented evidence, usual practice, opinion, case-series

a. Memantine: found effective in 2 double blinded and one single blinded RCT.
b. Lamotrigine: found effective in 2 double blinded RCTs
c. Topiramate: effective in 2 small double-blind RCTs, but poorly tolerated
d. Riluzole: inconsistent results in two RCTs
e. N-acetylcysteine: conflicting results from three RCTs, has to be studied further.

BASED ON THE EVIDENCE AND ITS RELATIVELY BETTER TOLERABILITY, MEMANTINE IS PREFERRED OVER LAMOTRIGINE AS THE FIRST CHOICE GLUTAMATERGIC AUGMENTING AGENT.
but low frequency rTMS over supplementary motor area (SMA) and orbitofrontal cortex (OFC) appear promising [29]. However, the evidence has not been very consistent. Overall, the findings have to be replicated in larger samples with long term follow-up. There is no convincing evidence that beneficial effects persist for longer than the trial period. The guideline recommends rTMS as an intervention for further research and not for routine clinical use.

3. Transcranial direct current stimulation (tDCS)

tDCS is another focal and superficial cortical modulatory intervention, which either increases or decreases the excitability of the underlying cortex depending on the polarity of the stimulating electrode. There are only a few case reports and an open-label trial on tDCS in OCD. It has to be evaluated more systematically before it can be recommended for clinical use in OCD.

NEUROSURGICAL PROCEDURES

1. Ablative neurosurgery

Ablative neurosurgical procedures involve producing lesions in specific regions of the CSTC circuit, which is hypothesized to be dysfunctional in OCD. Reliable lesions can be produced with the help of “invasive” stereotactic surgery or “non-invasively” with the help of image guided gamma radiation. Anterior cingulotomy and a refined version of capsulotomy known as ‘gamma ventral capsulotomy’ are practiced in treatment refractory OCD in a few centers. Due to the irreversible nature, these procedures are generally employed in treatment refractory patients (Table 10). Evidence primarily in the form of uncontrolled studies suggests that around 40-60% of patients improve over 6-24 months following surgery. There is some suggestion that capsulotomy may be more effective procedure in OCD [30] and that its efficacy may be similar to that of deep brain stimulation (DBS)[31]. Surgery may be associated with short-term and persistent adverse effects including personality changes, seizures and cognitive adverse effects although rates are not high.

2. Deep brain stimulation

Deep brain stimulation (DBS) is a potentially reversible procedure involving high frequency stimulation of implanted electrodes in the brain. Although the mechanism of action is poorly understood, it is hypothesized to modify dysfunctional circuits. DBS for OCD has been evaluated in sham controlled studies targeting nucleus accumbens, ventral capsule/ventral striatum, anterior limb of internal capsule, ventral caudate and subthalamic nucleus. A recent meta-analysis found a responder rate of 60% with a mean YBOCS reduction of around 45% [32]. DBS is an invasive procedure and is associated with short term and long term adverse effects. Further, the battery needs to be replaced periodically which may be quite expensive. DBS can be recommended in carefully selected refractory OCD patients (Table 10) after discussion regarding the pros and cons of the procedure.

The neurosurgical procedures are not curative in nature and the procedures are only one aspect of a comprehensive treatment program which should continue following surgery.

Surgical procedures may be considered only in selective patients after careful evaluation of patients for treatment refractoriness, severity of illness and comorbidities. Patients should be explained about the realistic possibility of benefits and risks. They should be evaluated by an independent team consisting of a psychiatrist, a neurologist and a neurosurgeon for suitability for surgery. The treatment should be conducted under close collaboration of a team of psychiatrist, neurosurgeon, radiotherapist, imaging specialist and psychologist with close monitoring of adverse effects. Suggested criteria for suitability to undergo surgery are shown in Table 10.

Table 10: Selection criteria for surgery

| Criteria for Surgery |
|----------------------|
| 1. Severe (YBOCS >28) and chronic unremitting OCD |
| 2. The disorder is causing substantial distress and impairment in functioning (GAF ≤45) |
| 3. The following treatment options tried systematically without appreciable effect on the symptoms |
| • Adequate trial with at least 2 of the SSRI antidepressants for at least 3 months each |
| • Treatment with clomipramine at optimum dosage for at least 3 months unless poorly tolerated |
| • Augmentation with at least 2 agents, one of them being an atypical antipsychotic: atypical antipsychotic (risperidone, aripiprazole), clomipramine, memantine, ondansetron/granisetron |
| • At least one adequate trial of cognitive behavior therapy (at least 20 sessions of exposure and response prevention) or demonstrated inability to tolerate the anxiety due to therapy |
| • Previous treatment trials have not been abandoned prematurely due to solely mild side effects |
| 4. Patient gives informed consent |
| 5. Willing to participate in the pre-operative evaluation and post-operative follow-up |
| Relative contraindications: |
| 1. Comorbid intellectual disability, psychosis, bipolar disorder and severe personality disorders |
| 2. Clinically significant and unstable neurologic illnesses |

PSYCHOLOGICAL TREATMENTS FOR OCD (TABLE 11)

A. Cognitive Behavioral Therapy (CBT) / Exposure and Response Prevention (ERP)

Consistently, CBT/ERP has been shown to be efficacious in the treatment of OCD [33]. All treatment guidelines have suggested the use of CBT as a first-line treatment option. CBT for OCD includes ERP.

CBT/ERP is a first-line treatment option for OCD. ERP is the most important component of CBT along with belief
Reddy, et al.: CPGs for OCD

**Table 11: Psychotherapy in OCD**

| Psychotherapy                                      | Strength of recommendation |
|----------------------------------------------------|----------------------------|
| Cognitive behaviour therapy (including exposure and response prevention) | A                          |
| Behaviour therapy (exposure and response prevention) | A                          |
| Mindfulness based cognitive behaviour therapy      | C                          |
| Acceptance and commitment therapy                  | C                          |
| Stress management and relaxation training          | C                          |
| Thought stopping                                    | C                          |
| Dynamic psychotherapy                              | C                          |

*Based on modified Strength of Recommendation Taxonomy (SORT)*

**CBT as an augmentation strategy**

It is uncertain whether initiating a combination of CBT/ERP and SSRIs is advantageous compared to either treatment alone. However, CBT/BT is found to be effective in augmenting SSRIs in partial/non-responders to SSRIs [34]. A recent study found CBT to be superior to risperidone and placebo in augmenting SSRIs in OCD [35]. Patients in the CBT group had significantly greater reductions in OCD symptom severity compared with participants taking risperidone or placebo. Risperidone was not superior to placebo on any outcome measures.

When facilities for CBT are available, CBT / BT is recommended as the first line augmenting strategy in partial/non-responders to SSRI treatment.

**Mode of CBT/ERP delivery and adaptations**

Although various models are available for CBT in OCD, the major components are psychoeducation, development of symptom hierarchy, cognitive restructuring and ERP (Table 12). The method of conducting ERP has been found to be important with ‘therapist–assisted’ ERP producing a greater change in symptom severity. Therapist-guided exposure is better than self-guided exposure. The numbers of CBT sessions have varied between 12 and 20 sessions across various studies. It has ranged from intensive daily 2 hour sessions for 5 days a week to less intensive twice weekly sessions in other studies.

Even though group CBT has been compared with individual CBT, the results have been mixed. While a couple of studies have reported comparable efficacy for group and individual forms of CBT, some other studies demonstrated the superiority of individual mode of CBT compared to the group CBT. Another adaptation of CBT which has been examined in the recent years is the internet based CBT (ICBT) and computerized CBT. They are found to be effective compared to supportive therapy / relaxation methods [36, 37].

Where resources are available, 15-20 hours of therapist assisted CBT / BT may be considered. The evidence for ICBT and computerized CBT is very preliminary and it may be recommended in certain circumstances where regular face-to-face CBT is not feasible.

**B. Other Psychological therapies**

1. **Acceptance and Commitment Therapy**
   
   This therapy aims to improve psychological flexibility through the practice of *acceptance* and mindfulness in addition to *commitment* and behavior modification exercises. Preliminary evidence suggests its benefits but it needs to be tested and compared with CBT in larger samples.

2. **Stress management and relaxation training**
   
   These have been conventionally used in many studies as control arm in studies CBT. Stress management and relaxation training may have non-specific effects but there is no evidence suggesting their efficacy in treatment of OCD.

3. **Mindfulness based cognitive therapy**
   
   Mindfulness based therapy is thought to be useful in OCD. Preliminary data suggests its utility in treating OCD. Protocols for RCT are published but there is no published evidence in the literature in clinical population.

4. **Family inclusive treatments**
   
   Family-inclusive treatment (FIT) approaches aim to include the family members in the treatment so as to improve the family functioning, facilitate behavioral therapy etc. Studies targeting family accommodation of obsessive-compulsive symptoms report greater improvements in patient functioning. Family members may be encouraged to participate in CBT since family accommodation of symptoms is associated with poorer treatment outcomes.

5. **Others**
   
   The other forms of psychological therapies with isolated studies include adjunct motivational interviewing to ERP and Eye Movement Desensitization and Reprocessing (EMDR). There is one study examining the role of brief dynamic therapy in OCD with negative result. In addition, the potential benefits of adding D-cycloserine prior to ERP sessions has been examined in few studies.

**MANAGEMENT AS PER THE DIFFERENT PHASES OF ILLNESS**

**Acute phase**

This includes decision on choice of treatment modality (SSRI vs. CBT), implementation of treatment, monitoring for the response and side-effects, and planning for sequential
Reddy, et al.: CPGs for OCD

S85

Indian J Psychiatry 59 (Supplement 1), January 2017

Table 12: Components of CBT for OCD

| Step                              | Components                                                                                                                                 |
|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Assessment                        | • Assess nature and severity of OCD symptoms (YBOCS symptom checklist and severity rating)                                                   |
|                                   | • Examine insight in to the OCD symptoms                                                                                                                                                            |
|                                   | • Assessment of safety behaviors and avoidance strategies employed by the patient                                                                                                                   |
|                                   | • Look for current comorbid conditions such as depression that may interfere with CBT                                                                                                                   |
|                                   | • Assess the motivation levels and personality attributes of the patient                                                                                                                                |
|                                   | • Family’s involvement (accommodating the symptoms, proxy compulsions, expressed emotions) needs to be explored                                                                                  |
| Psychoeducation                   | • Educate regarding the nature of obsessions and compulsions                                                                                                                                            |
|                                   | • Explain the cycle of propagation of obsessions through performing compulsions and by avoiding the stimuli                                                                                           |
|                                   | • Discuss in detail the rationale behind CBT (concepts of habituation, fear extinction and the role of dysfunctional beliefs)                                                                         |
|                                   | • Educate the family members about principles in CBT                                                                                                                                                    |
|                                   | • Develop a collaborative understanding of the formulation with the patient (e.g., the goal is to eliminate fear of HIV infection and not reduce/prevent the chances of contracting HIV) |
| Formulate the therapy             | • Formulation needs to be personalized                                                                                                                                                                |
|                                   | • Identify the specific cognitive distortions (maladaptive thinking patterns) such as exaggerated threat perception, inflated responsibility, perfectionism, need to control thoughts etc. |
|                                   | • Develop a collaborative understanding of the formulation with the patient (e.g., the goal is to eliminate fear of HIV infection and not reduce/prevent the chances of contracting HIV) |
| Handling the thoughts             | • Explain the “neutral spectatorship” principle towards obsessions (don’t interpret them, observe )                                                                                                    |
|                                   | • Demonstrate how offering active resistance to obsessions is counterproductive and increases their salience                                                                                          |
| Challenging the dysfunctional beliefs | • Foster the practice of gathering evidence for the thoughts (how likely would it happen/what is the worst consequence/less threatening alternative explanations etc.) |
|                                   | • Socratic questioning initiated                                                                                                                                                                       |
|                                   | • Examining the faulty appraisals with examples                                                                                                                                                        |
|                                   | • Preparing for behavioral experiments (exposure and response prevention)                                                                                                                              |
| Behavioral Experiments-Exposure and Response prevention | • ERP forms the core of CBT. Exposure to anxiety provoking situations in a graded manner with negotiations and contracts at every step                                                                 |
|                                   | • Rationale of ERP with examples-explain the habituation and extinction principle with the aim of anxiety reduction as well as disconfirmation of the fears                                                    |
|                                   | • Make a list of anxiety provoking situations/trigger in a hierarchical manner using subjective units of distress (0 to 10 subjective rating by the patient)                                               |
|                                   | • Expose the patient starting from the lowest anxiety provoking situation and gradually escalate the level. Each session lasting for 1-1 ½ hours , till the patient experiences reduction in distress/anxiety |
|                                   | • Homework assignments, consistent performance of ERP tasks insisted upon                                                                                                                              |
| Relapse prevention                 | • Explain that treatment is a continuous process                                                                                                                                                       |
|                                   | • Periodic booster sessions to review the situation and to troubleshoot emerging issues                                                                                                                |
|                                   | • Anticipation of future concerns such as change in the form of symptoms, relapse under stress, emergence of subtle avoidance behaviors etc                                                                 |
|                                   | • Encourage regular work and other normal behaviors                                                                                                                                                     |

**treatment trials if initial treatments failed to produce satisfactory improvement.**

**Maintenance treatment (How long the treatment should be continued?)**

There is evidence for ongoing improvement with continued use of SSRIs and clomipramine in long term continuation studies for a period of up to 1 year[18]. Guidelines recommend continuation of SSRIs / clomipramine for at least 1-2 years after achieving remission. Clinical experience dictates that discontinuation of medication beyond that period may be associated with increased chance of relapse. Hence discontinuation of medications should be carefully considered based on individual patient factors including severity and duration of illness, past history of relapse on discontinuation, residual symptoms, comorbidities etc. Most patients may require continued pharmacotherapy to prevent relapses. Medications are generally recommended to be continued at the same dose that resulted in improvement, unless the dosage is not tolerated.

**MANAGEMENT OF COMORBID CONDITIONS**

**Depression and Anxiety disorders**

Most common co-occurring illness is major depression. The Pharmacological treatment strategy does not change much, however in severe depression CBT/ERP for OCD needs to be held on until the patient recovers from depression. Severe depression with prominent suicidal ideas needs to be evaluated thoroughly and ECT may be considered if indicated. Comorbid dysthymia is common and may require individual therapy.

Comorbid anxiety disorder needs to be treated aggressively since untreated anxiety disorder may contribute to poor treatment outcome. Comorbid anxiety disorders may require CBT in addition to SSRIs.

**Tic disorders**

Tic disorders show best response to antipsychotics (haloperidol, pimozide, risperidone and aripiprazole).
Although antipsychotics may be more effective, adrenergic \( \alpha_2 \) agonists (clonidine and guanafacine) may be tried first to treat tics in view of adverse effects associated with antipsychotics. Habit-reversal therapy (HRT) is a potential first-line treatment option instead of or in combination with pharmacotherapy.

OCD patients with tic disorders may require a combination of an SSRI and an antipsychotic. There is evidence that OCD comorbid with tic disorders may not respond satisfactorily to SSRI alone.

**Bipolar Disorder**

Comorbid bipolar disorder calls for a different treatment strategy because SSRIs are well known to cause/exacerbate hypomania or mania. Mood stabilization should be the primary goal in treating OCD-bipolar patients [38]. In many patients with comorbid bipolar disorder, OCD often manifests / increases in severity in depressive episodes but improves in mania / hypomania episodes. In such patients, treatment with mood stabilizer alone may be considered. If OCD persists outside of the mood episodes, CBT may be preferred over SSRIs. However, if patient requires an SSRI, it has to be prescribed under the cover of mood stabilizers or an atypical antipsychotic.

**Psychosis**

OC symptoms and OCD are not uncommon in those with schizophrenia; up to 25% of the schizophrenia patients report clinically significant OCD symptoms. SSRIs may be used in treating OCD comorbid with schizophrenia, but there is limited published evidence. Some atypical antipsychotics such as clozapine, risperidone and olanzapine may induce or even worsen OCD symptoms. In case of drug-induced OC symptoms, if feasible, one may consider reducing dose or changing to another antipsychotic.

**Personality disorders**

20% of the participants suffer from at least one comorbid personality disorder (PD). The most common are obsessive-compulsive, narcissistic and anxious avoidant personality disorders. Presence of PD can complicate the course and outcome. OCD patients with different comorbid PDs differ in their therapeutic response to treatment. Borderline, obsessive-compulsive and schizotypal personality disorders can contribute to poor outcome. There are no systematic studies comparing the effects of treatment in OCD coexisting with PD. Generally it is agreed upon that a combination of medications, CBT-ERP and individual therapy are advocated.

**OCD during pregnancy and lactation**

Medication should be guided primarily by its safety data, severity of the illness, and benefit vs. risk to the developing fetus. For newly diagnosed OCD during pregnancy and in the post-partum period, CBT/ERP is the preferred option [39]. Pre-pregnancy counseling for all women should include planning pregnancy, folic acid supplementation, discussion with patient and spouse regarding options, and active liaison with obstetricians, ultrasonologists and pediatricians.

Following is the summary of SSRIs in pregnancy and lactation:

1. If the patient is symptom-free for a long period, an attempt may be made to withdraw the SSRI gradually. However, a risk of relapse following discontinuation should be discussed.
2. Benefits vs. risks of continuing SSRIs during pregnancy should be discussed keeping in mind the fact that OCD can relapse following discontinuation.
3. SSRIs as a group do not appear to be major teratogens.
4. SSRIs, paroxetine in particular have been associated with increased risk for cardiac malformations (septal defects) (1.5-2%), as compared to the general population (1%) but the evidence is inconsistent. Paroxetine may be avoided; it is less safe than the other SSRIs.
5. Some studies have reported an association between SSRI use in first trimester and anencephaly, craniostenosis, and omphalocele. However, it must be emphasized that the risks are rare and absolute risks are small.
6. When taken in late pregnancy, SSRIs may increase the risk of persistent pulmonary hypertension by more than twofold in the newborn (absolute risk, 3 infants per 1000 exposed vs. 1.2 infants per 1000 unexposed).
7. SSRIs have also been associated with decreased gestational age, low birth weight and spontaneous abortion.
8. Following birth, serotonergic toxicity and antidepressant discontinuation symptoms may manifest, therefore it is important to liaise with pediatricians.
9. Sertraline, fluvoxamine and paroxetine are present in very low concentrations in plasma of breast-fed infants (<3% of maternal dose). It is surmised that they are relatively safe during breast feeding. With fluoxetine and citalopram, infants can receive up to 15% of the maternal dose.

**OCD in child and adolescent population**

SSRIs and clomipramine are efficacious in treating OCD and are superior to placebo with modest effect size [40]. CBT has superior efficacy compared to SSRIs in children [40]. A combination of CBT and SSRI seems to have no additional advantage over CBT alone indicating that SRI treatment adds little to concomitant CBT. However, combined treatment is better than SSRI alone. In partial responders to SSRIs, adding CBT is superior and efficacious as compared to continuing a SSRI. In view of superior efficacy of CBT, many guidelines advocate CBT as the first line treatment in children. In children, where facilities are available, CBT may be preferred over SSRIs as the first-line treatment. In children with severe OCD, a combination of CBT and SSRI is recommended over SSRI alone. SSRIs are the alternative first-line treatment for OCD in children in situations where
**Table 13: Side-effects of SSRIs**

| Symptom                  | Comment                                                                 | Management                                                                 |
|--------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Drowsiness, insomnia     | All SSRIs can cause somnolence                                          | Drowsiness: Prescribe bulk of dose at bedtime. Insomnia: Fluoxetine may be prescribed in the morning. Benzdiazepines, Trazadone or zolpidem may be used for insomnia. |
| Hypotension              | Not a usual side-effect                                                 | SSRIs are generally safe in patients with cardiovascular diseases including the post myocardial infarction period. Sertraline appears to be the safest. Citalopram and escitalopram should be used with caution in those at risk for arrhythmia. |
| Conduction disturbances  | SSRIs have no effect on QTc and are not associated with arrhythmias and conduction disturbances. Exception: Citalopram (? escitalopram) is associated with dose related increase in QTc and Tosades de pointes in overdose. | Most get over the side-effects. If they are troublesome, reduce the dose or change the SSRI. |
| Anticholinergic           | Not prominent with SSRIs except with paroxetine                         | Common GI side-effects usually settle down with continued use. If they persist, reduce dose or change the SSRI. Proton pump inhibitors may be useful. |
| Gastrointestinal         | Nausea, vomiting, diarrhea, dyspepsia and anorexia are common. Nausea more common with Fluvoxamine. Paroxetine can cause constipation. SSRIs may increase the risk of gastrointestinal bleeding. | Use SSRIs with caution when co-administered with aspirin, NSAIDs or oral anticoagulants. |
| Neurological             | Headache (and worsening of migraine), tremors and rarely akathisia, extrapyramidal symptoms, seizures and dyskinesias. | Fine tremors, akathisia may respond to propranolol. Extrapyramidal symptoms respond to trihexiphenidyl. Headache responds to acetaminophen prn. Increase the dose gradually; benzodiazepines may help. |
| Activation/agitation     | Usually seen with fluoxetine                                           | Always use under the cover of mood stabilizers or atypical antipsychotics. Identify if other causes such as depression and medical causes are contributing to sexual dysfunction. If possible, reduce dose or employ drug holidays but this approach has the risk of relapse. Change to other SSRI may be considered. Sildenafil or tadafalil, cyproheptadine, and bupropion may improve sexual dysfunction. |
| Switch to mania/hypomania| Risk of switch to mania/hypomania is known in those with bipolar disorder | Risks of switch to mania/hypomania are known in those with bipolar disorder. Increase the dose gradually; benzodiazepines may help. |
| Sexual dysfunction       | All SSRIs are associated with sexual dysfunction; prevalence may be as high as 60% All phases of sexual response are affected including decreased libido, erectile dysfunction, decreased vaginal lubrication, delayed orgasm, and ejaculatory delay. Erectile dysfunction and ejaculatory delay are worse with paroxetine compared to other SSRIs. | Identify if other causes such as depression and medical causes are contributing to sexual dysfunction. If possible, reduce dose or employ drug holidays but this approach has the risk of relapse. Change to other SSRI may be considered. Sildenafil or tadafalil, cyproheptadine, and bupropion may improve sexual dysfunction. |
| Hyponatremia             | SSRIs are associated with hyponatremia because of syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Risk factors include old age, female gender, co-administration of drugs known to cause hyponatremia (diuretics, NSAIDs, ACE inhibitors etc), reduced glomerular filtration rate, and medical comorbidity. | Hyponatremia is common in elderly. Monitoring is essential. Referral to specialists if serum level is <125 mmol/L. |
| Serotonin syndrome      | Nausea, vomiting, diarrhea, tremor, sweating, disorientation, restlessness, agitation, headache, increased heart rate, changes in blood pressure & temperature, twitching, tremors, myoclonic jerks, hyperreflexia, high fever, seizures, arrhythmias, agitation, confusion, delirium and even coma. Can occur with very high doses of SSRIs or a combination of SSRIs in high doses. | Stop the offending drugs immediately. Symptomatic management: benzodiazepines to treat agitation and/or seizures, intravenous fluids to maintain hydration, anti-emetic and anti-pyretic medications. In severe cases, cyproheptadine (8‑12mg/day) is given orally. |
| Weight gain              | Known with all SSRIs although there may be initial weight loss. Paroxetine is associated with weight gain more than other SSRIs. | If weight gain is significant, an attempt may be made to shift to another SSRI. Lifestyle modification may be discussed. Drugs such as topiramate may be tried. |
| Suicidal behavior        | SSRIs are associated with increased suicidal ideation and attempts in children. Abrupt discontinuation may cause discontinuation syndrome, particularly with short-acting drugs (dizziness, nausea, vomiting, diarrhea, headache, fever, sweating, chills, insomnia, paresthesias, electric-shock-like sensations, anxiety, agitation, irritability, disorientation). Reported mostly with paroxetine. Typically occur within a week of discontinuation. | Children on SSRIs should be monitored closely for emergence of suicidal thoughts. Withdraw gradually. Taper SSRI by no more than 25% per week. |
| Discontinuation syndrome |                                                                       | Caution should be exercised in combining ceratin SSRIs with drugs that are essentially metabolized by cytochrome P-450 system. SSRIs can elevate clomipramine level resulting in more side effects, particularly seizures and serotonin syndrome; this combination should be used judiciously and patients have to be monitored closely. |

CBT is either not available or the child cannot comply with CBT. **SSRIs in medically ill** SSRIs are generally safe in patients with cardiovascular...
Table 14: Summary of treatment recommendations

- Establish a diagnosis of OCD. Assess for comorbid conditions such as depression and anxiety disorders and certain personality disorders. It is important to treat comorbid conditions since untreated comorbidity may contribute to poor outcome.
- Where feasible, employ instruments such as the YBOCS to assess symptoms and their severity.
- Psychoeducation of the patient and family about OCD, its cause and course and treatment options is essential.
- SSRIs and CBT are the first-line evidence based treatment options for OCD. In the Indian context, SSRIs are often the preferred first-line treatment options.
- All SSRIs are equally effective but they differ in their side-effect profile.
- Choice of an SSRI for an individual patient is based on factors such as previous response, tolerability, acceptability, adverse effects, cost and drug interactions.
- Most patients require higher than the usual antidepressant dose of an SSRI.
- There is no convincing evidence that clomipramine is superior to SSRIs. Since clomipramine has many side-effects, it is not recommended as the first-line treatment option. It may be considered if patient fails to respond to 2 or more SSRIs.
- An adequate trial of an SSRI (or clomipramine) should be for at least 12 weeks in optimum doses. Premature discontinuation is not recommended since most patients show improvement gradually over several weeks.
- SSRIs have to be continued at least for 1-2 years after remission. However, most patients may require indefinite continued treatment with a SSRI to prevent relapses particularly those with severe and chronic illness, past history of relapse on discontinuation and clinically significant residual symptoms. SSRIs are generally recommended to be continued at the same dose that resulted in improvement, unless the dose is not tolerated.
- CBT alone may be recommended in mild to moderately ill patients if facilities for CBT exist. However, most severely ill patients benefit from a combination of an SSRI and CBT.
- In partial responders and non-responders to SSRIs, addition of CBT is recommended as the first option. If CBT is not feasible, an atypical antipsychotic in low dose (risperidone and aripiprazole) may be added as an augmenting agent.
- Inpatient treatment is recommended for severely ill, treatment resistant patients and for comorbid conditions such as severe depression.
- ECT has no proven value in the treatment of OCD. There is inconsistent evidence regarding the efficacy of rTMS; hence it is not recommended for routine use.
- DBS and ablative surgery may be considered in chronic, severely ill treatment refractory OCD patients.


problems. Citalopram (or escitalopram) is associated with arrhythmias but the risk is low and may not be clinically significant, but may be used with caution or avoided in those at risk for arrhythmias. SSRIs are widely used to treat depression in diabetes. They may improve diabetic parameters: improvement in HbA1c levels, reduced insulin requirement, enhanced insulin sensitivity and improved glycemic control. SSRIs are not hepatotoxic, but they need to be used in lower doses and with caution in the presence of significant hepatic impairment since all SSRIs are biotransformed in liver. All SSRIs are metabolized by the Cytochrome P450 system and fluoxetine, fluvoxamine, and paroxetine also significantly inhibit P450 enzymes. Therefore, these agents may potentially interfere with wide variety of other medications. Interactions with other drugs need to be considered, particularly in elderly who are likely to be on many medications for other medical conditions. Citalopram / escitalopram and sertraline do not substantially inhibit P450 enzymes and therefore are associated with less drug interactions. All SSRIs are renally excreted. Depression is common in those with chronic kidney disease (CKD) and end stage renal disease (ESRD). If indicated SSRIs are the preferred antidepressants. SSRIs such as paroxetine, citalopram and escitalopram may have to be administered in lower doses in CKD and ESRD in the background of compromised renal functions. Since many patients with CKD and ESRD also suffer from cardiovascular disorders, citalopram (and perhaps escitalopram) may be used with caution since high doses of citalopram is associated with QTc prolongation and torsades de pointes.

Side Effects of SSRIs

The dosage of anti-obsessive drugs is usually higher than the usual anti-depressant dose; hence it is important for the clinician to discuss regarding the common side-effects. This issue is important because patients need to be on medications for a long duration. Sometimes an adjustment in dose or a switch in the time of the day the dose is taken is all that is needed. Rarely, stopping a particular medication and switching to another medication may be required. Side-effects of SSRIs and possible remedies are given in Table 13.

Summary

Recommendations are summarized in Table 14. The SSRIs and CBT are the first-line treatment options for OCD. CBT alone may be tried in mild to moderately ill patients if facilities for CBT are available. In severe OCD, a combination of SSRI and CBT is recommended. In the Indian context, SSRIs are the preferred first-line treatment for OCD because of limited resources for delivering CBT. SSRIs are effective, well tolerated and safe. For partial responders and non-responders to SRIs, CBT is an effective augmenting agent followed by atypical antipsychotics. Although an attempt may be made to taper and stop SSRI after 1-2 years of sustained remission, most patients may require indefinite continued treatment with a SSRI. DBS and ablative surgery may be considered in chronic, severe OCD if other established treatment options have failed to produce any clinically significant improvement.

REFERENCES

1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010): The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry. 15:53-63.
2. Sharma E, Thennarasu K, Reddy YC (2014): Long-term outcome of obsessive-compulsive disorder in adults: a meta-analysis. The Journal of Clinical Psychiatry. 75:1019-1027.
3. Simpson HB, Reddy YC (2014): Obsessive-compulsive disorder for ICD-11: proposed changes to the diagnostic guidelines and specifiers. Revista Brasileira de Psiquiatria. 36 Suppl 1:3-13.
4. Stein DJ, Kogan CS, Almaca M, Fineberg NA, Fontenelle LF, Grant JE, et al. (2016): The classification of Obsessive-Compulsive and Related
Disorders in the ICD-11. *Journal of Affective Disorders*. 190:663-674.
5. Amerio A, Odono A, Liapis CC, Ghaemi SN (2014): Diagnostic validity of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. *Acta Psychiatr Scand*. 129:343-358.
6. Zutshi A, Reddy YC, Thennarasu K, Chandrasekhar CR (2006): Comorbidity of anxiety disorders in patients with remitted bipolar disorder. *European Archives of Psychiatry and Clinical Neurosciences*. 256:428-436.
7. Shashidhara M, Sushma BR, Viswanath B, Math SB, Janardhan Reddy YC (2015): Comorbid obsessive compulsive disorder in patients with bipolar-I disorder. *Journal of Affective Disorders*. 174:367-371.
8. Mahasuar R, Janardhan Reddy YC, Math SB (2011): Obsessive-compulsive disorder with and without bipolar disorder. Psychiatry and Clinical Neurosciences. 65:423-433.
9. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1999): The Yale-Brown Obsessive Compulsive Scale: I. Development, and reliability. *Archives of General Psychiatry*. 46:1006-1011.
10. Scailli L, Riddle MA, McSwiggin-Hardin M, Ort SJ, King RA, Goodman WK, et al. (1997): Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. *Journal of the American Academy of Child and Adolescent Psychiatry*. 36:844-852.
11. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American Psychiatric A (2007): Practice guideline for the treatment of patients with obsessive-compulsive disorder. The American Journal of Psychiatry. 164:54-53.
12. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. (2014): Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. *Journal of Psychopharmacology*. 28:403-439.
13. National Collaborating Centre for Mental Health(UK). (2006): Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder. *The British Psychological Society*. 3:730-739.
14. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ (2015): Antipsychotic augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. *JAMA Psychiatry*. 70:1190-1199.
15. Ebell MH, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1999): The Yale-Brown Obsessive Compulsive Scale: I. Development, and reliability. *Archives of General Psychiatry*. 46:1006-1011.
16. Scailli L, Riddle MA, McSwiggin-Hardin M, Ort SJ, King RA, Goodman WK, et al. (1997): Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. *Journal of the American Academy of Child and Adolescent Psychiatry*. 36:844-852.

Reddy, et al.: CGPs for OCD Indian J Psychiatry 59 (Supplement 1), January 2017
Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. *Molecular Psychiatry*. 11:495-504.

45. Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA (1998): The Brown Assessment of Beliefs Scale: reliability and validity. *The American Journal of Psychiatry*. 155:102-108.

46. Neziroglu F, McKay D, Yaryura-Tobias JA, Stevens KP, Todaro J (1999): The Overvalued Ideas Scale: development, reliability and validity in obsessive-compulsive disorder. *Behaviour Research and Therapy*. 37:881-902.

47. Obsessive Compulsive Cognitions Working G (2005): Psychometric validation of the obsessive belief questionnaire and interpretation of intrusions inventory—Part 2: Factor analyses and testing of a brief version. *Behaviour Research and Therapy*. 43:1527-1542.

48. Calvocorelli L, Lewis B, Harris M, Trufan SJ, Goodman WK, McDougle CJ, et al. (1995): Family accommodation in obsessive-compulsive disorder. *The American Journal of Psychiatry*. 152:441-443.

49. Hazari N, Narayanaswamy JC, Arunmugham SS (2016): Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder. *Expert Review of Neurotherapeutics*. 16:1175-1191.